Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754647 | 0.89 | DPP8 (0.47) | ALDH1A1KDM4EDPP8KMT2ACHRM1 | |
| SCHEMBL25754638 | 0.82 | DPP8 (0.38) | DPP8CHRM1 | |
| SCHEMBL14843282 | 0.80 | POLB (0.47) | POLBHSD17B10TSHRGAAPHGDH | |
| SCHEMBL17152212 | 0.79 | DPP4 (0.48) | POLBHSD17B10TSHRGAAPHGDH | |
| SCHEMBL17152548 | 0.77 | DPP4 (0.49) | POLBHSD17B10TSHRGAAPHGDH | |
| SCHEMBL23514549 | 0.76 | PHGDH (0.46) | POLBHSD17B10TSHRGAAPHGDH | |
| SCHEMBL23514438 | 0.76 | PHGDH (0.46) | POLBHSD17B10TSHRGAAPHGDH | |
| Hydrochloric Acid SCHEMBL23499910 | 0.74 | PHGDH (0.45) | POLBHSD17B10TSHRGAAPHGDH | |
| SCHEMBL25754641 | 0.73 | TSHR (0.36) | TSHRGAAPHGDHMGLLSIGMAR1 | |
| SCHEMBL10051736 | 0.73 | POLB (0.53) | POLBHSD17B10TSHRGAAPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | POLB 4028/4885HSD17B10 2815/4885TSHR 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.